Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe

BACKGROUND: Approximately 164,000 deaths yearly are due to shigellosis, primarily in developing countries. Thus, a safe and affordable Shigella vaccine is an important public health priority. The GSK Vaccines Institute for Global Health (GVGH) developed a candidate Shigella sonnei vaccine (1790GAHB)...

Descripción completa

Detalles Bibliográficos
Autores principales: Launay, Odile, Lewis, David J.M., Anemona, Alessandra, Loulergue, Pierre, Leahy, Jo, Sciré, Antonella Silvia, Maugard, Anaïs, Marchetti, Elisa, Zancan, Stefano, Huo, Zhiming, Rondini, Simona, Marhaba, Rachid, Finco, Oretta, Martin, Laura B., Auerbach, Jochen, Cohen, Daniel, Saul, Allan, Gerke, Christiane, Podda, Audino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552227/
https://www.ncbi.nlm.nih.gov/pubmed/28735965
http://dx.doi.org/10.1016/j.ebiom.2017.07.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552227/
https://www.ncbi.nlm.nih.gov/pubmed/28735965
http://dx.doi.org/10.1016/j.ebiom.2017.07.013

Ejemplares similares